📢 Nous ouvrons notre capital pour libérer les patients de la douleur chronique 📢

Pour devenir actionnaire,  c’est par ici !

Groundbreaking non-pharmaceutical and clinically validated therapy for fibromyalgia.

Remedee Labs aims to make its solution a standard treatment for fibromyalgia

Remedee Labs’ solution based on the first millimeter wave endorphin stimulator wristband is now the 1st dedicated technological solution for fibromyalgia to have its benefits clinically validated in Europe. The results will be presented on Monday, November 13 by pain specialist Dr. Caroline Maindet at the annual meeting of the American College of Rheumatology (ACR) in San Diego (USA). This clinical trial included 170 patients suffering from fibromyalgia in over 8 centers in France.
bracelet Remedee endorphines ondes millimétriques

About the FIBREPIK study

étude fibrepik
fibrepik fibromyalgia

FIQ Score ≥39/100, from 8 French chronic pain care centers

The FIQ questionnaire is the standard clinical test used to assess the impact of fibromyalgia on patients’ quality of life. It covers physical activity, work, depression, anxiety, sleep, pain, stiffness, fatigue, and feelings of well-being.

A 14% decrease in the total FIQ score is considered clinically significant (Bennett et al. 2009.

Procedure: 2 Groups

fibrepik groups

The Remedee Labs Therapy

bracelet remedee stimulateur d'endorphines neuromodulation ondes millimétriques

1st millimeter wave endorphin stimulator



application mobile

Mobile Application

Remedee Labs has developed an innovative, comprehensive non-pharmaceutical solution based on a biopsychosocial approach that takes patients’ biological, psychological, and social factors into account. The solution combines Remedee Labs’ millimeter waves neuromodulation technology (validated by the EPIKARTHROSE study) with a personalized support program for long-term improvement in quality of life.

Study Results

Significant improvement in quality of life for 6 out of 10 patients

The results showed a clear improvement in patients’ quality of life. 55.1% of participants reduced their Fibromyalgia Impact Questionnaire (FIQ) score after 3 months of use. This figure rises to 62.3% if we consider people who have complied with the correct use of the solution in the clinical protocol (per-protocol results). Over half of patients (53%) went from severe to moderate intensity of fibromyalgia. That improvement remained in place at 6 months.
fibromyalgia treatment FIQ clinical study Fibrepik

Improvements in the main symptoms of fibromyalgia

Participants also showed a significant improvement in the main symptoms of fibromyalgia, with a significant decrease in pain, fatigue, anxiety, and depression, as well as improved sleep quality.


Sleep & Fatigue




Depression & Anxiety

Patients confirmed the improvement

Over 75% of patients reported an improvement in their health (Patient impression of change scores) after 3 months of use.

Perceived benefit of therapy was measured using the Patient Global Impression of Change (PGIC) questionnaire.

treatment fibromyalgia
pgic fibromyalgia
PGIC fibromyalgie
Caroline Maindet

Providing care for patients suffering from fibromyalgia is currently a major public health challenge. The positive results of the FIBREPIK study are very encouraging. Remedee Labs’ solution fits perfectly into a coordinated care approach, in which non-pharmaceutical treatments are the first choice

Docteur Caroline Maindet

, Pain Specialist at Grenoble Alpes University Hospital and lead investigator for the FIBREPIK study

Fibromyalgia: an invisible and severely debilitating disease

fibromyalgia symptoms
fibromyalgia in europe data

Fibromyalgia is a form of chronic widespread pain, associated with hypersensitivity to pain and a range of other symptoms, particularly sleep and mood disorders. It has a severe impact on quality of life and social and professional activities.

According to the collective expertise of INSERM, the French national medical research institute, about 2% of the French population has fibromyalgia. Women make up the majority of patients (80% to 90%). There is currently no specific treatment for fibromyalgia.

Management of the condition is based on multidisciplinary expertise. The standard of care for fibromyalgia essentially consists of non-pharmaceutical treatments, particularly adapted physical activity (APA) led by a professional. Counseling is also an important component of care. It is not simply a default option; in fact, it aims to improve pain modulation, which is altered by fibromyalgia. In most cases, it involves cognitive behavioral therapy (CBT) and patient education. Pharmaceutical treatments such as pain relievers, anti-depressants and anti-seizure drugs can only be prescribed at a later stage; however, their use must remain occasional.

« Today, there is no dedicated treatment for fibromyalgia patients. They need multi-disciplinary care centered on non-pharmaceutical treatment. Unfortunately, that type of care is not always available at chronic pain research and treatment centers due to the lack of dedicated resources. That means the non-pharmaceutical therapy offered by Remedee Labs, which has shown very positive clinical results, is a major advance in fibromyalgia management because it provides a holistic approach and creates a personal connection through personalized coaching. Since fibromyalgia patients often struggle financially, we hope that this therapy will be covered by social security very soon”


Last News